Southwest Family Medicine Associates
Southwest Family Medicine Associates
Dallas, Texas, United States13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06935370 | |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06424288 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 2 | 2026-09-29 | NCT07448038 | |
| A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 3 | 2026-09-25 | NCT06679140 | |
| Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07157774 | |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Arrhythmias, Cardiac, Embolism, Embolism and Thrombosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, atrial fibrillation, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic stroke, lung disorder, nervous system disorder, pulmonary embolism, respiratory system disorder, stroke disorder, thrombotic disease, vascular disorder, venous thromboembolism | Recruiting | Phase 3 | 2026-09-17 | NCT07430956 | |
| A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | Disorders of Excessive Somnolence, Dyssomnias, Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, idiopathic hypersomnia, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-09-14 | NCT07500090 | |
| Screening for High Frequency Malignant Disease | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2026-07-06 | NCT05117840 | |
| A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | Primary Sjogrens Disease | Active, not recruiting | Phase 3 | 2026-04-16 | NCT06684847 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 | |
| Eversense® Non-adjunctive Use Post Approval Study | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus, type 2 diabetes mellitus | Active, not recruiting | Not applicable | 2025-08-13 | NCT04836546 | |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Diabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2022-12-08 | NCT04083339 |